SPRYCEL

Compare SPRYCEL  to:
Compare
Compare

Generic Name for SPRYCEL

Dasatinib 20mg, 50mg, 70mg; 100mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SPRYCEL

Tyrosine kinase inhibitor.

Manufacturer of SPRYCEL

Bristol-Myers Squibb

Indications for SPRYCEL

Chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

Adult dose for SPRYCEL

Swallow whole. ≥18yrs: Chronic phase CML: 100mg once daily. Doses of up to 140mg once daily have been used. Accelerated phase CML, myeloid or lymphoid blast CML, Ph+ ALL: 140mg once daily. Doses of up to 180mg once daily have been used. Concomitant CYP3A4 inhibitors (see Interactions): consider reducing dose. Concomitant CYP3A4 inducers (see Interactions): consider increasing dose. See literature for dose adjustments with toxicity.

Children's dosing for SPRYCEL

<18yrs: not recommended.

Precautions for SPRYCEL

History of QT prolongation. Proarrhythmic conditions. Cumulative high-dose anthracycline therapy. Hypokalemia, hypomagnesemia; correct electrolyte imbalances before starting therapy. Monitor for pleural effusions. Obtain CBCs weekly for the first 2 months, then monthly thereafter. Hepatic impairment. Pregnancy (Cat.D; use adequate contraception); nursing mothers: not recommended.

Interactions for SPRYCEL

Avoid potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, voriconazole), grapefruit juice. May be antagonized by CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital); St. John's wort: not recommended. Separate dosing of antacids by at least 2 hours; H2 blockers, proton pump inhibitors: not recommended. May potentiate drugs metabolized by CYP3A4 (eg, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, ergot alkaloids). Caution with concomitant anticoagulants or drugs that inhibit platelet function.

Adverse Reactions for SPRYCEL

Myelosuppression (eg, thrombocytopenia, neutropenia, anemia), fluid retention (eg, ascites, edema, pleural and pericardial effusions), GI upset, headache, dyspnea, rash, fatigue, hemorrhage (eg, CNS, GI); QT prolongation.

How is SPRYCEL supplied?

Tabs 20mg, 50mg, 70mg—60
100mg—30

Related Disease:

Leukemia, acute lymphoblastic
Leukemia, chronic myelogenous
Neoplasms

Related Resources

FDA grants priority review to Tasigna for newly diagnosed chronic myeloid leukemia

February 19, 2010

Novartis announced that Tasigna (nilotinib) 200 mg capsules has been granted priority review by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.

Orphan drug designation granted to ENMD-2076 for acute myeloid leukemia (AML)

February 16, 2010

EntreMed, Inc. was granted orphan drug designation by the FDA for its lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

Phase 3 study of perifosine for metastatic colon cancer

February 03, 2010

Æterna Zentaris and Keryx Biopharmaceuticals announced agreement with the FDA regarding a Special Protocol Assessment on its Phase 3 trial for perifosine (KRX-0401) for the treatment of refractory metastatic colorectal cancer.

Tykerb approved for metastatic breast cancer treatment in combination with letrozole

February 01, 2010

GlaxoSmithKline announced that the FDA has approved Tykerb (lapatinib tablets) in combination with letrozole (Femara, from Novartis) as a first-line, all-oral regimen for the treatment of postmenopausal women with hormone receptor (HR) positive metastatic breast cancer that overexpresses the HER2 receptor.